Overview

Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors

Status:
Terminated
Trial end date:
2019-01-23
Target enrollment:
Participant gender:
Summary
This is a Phase II study to evaluate the activity of brentuximab vedotin in relapsed/refractory non-seminomatous germ cell tumors (NSGCT).
Phase:
Phase 2
Details
Lead Sponsor:
Costantine Albany
Nabil Adra
Treatments:
Antibodies, Monoclonal
Brentuximab Vedotin